(turmeric), and have received much attention due to their pleiotropic anticancer properties. Recent evidence suggests that curcumin and analogs prevent the activation of a variety of signaling pathways, including the MAPK, PI3K/Akt, and NF-kB pathways, resulting in the induction of apoptosis, prevention of proliferation, and suppression. In addition to these processes, curcumin has been shown to enhance the efficacy of the conventional anti-cancer modalities such as radiation and chemotherapy. By suppressing the expression of matrix metalloproteinases (MMPs), which are enzymes that break down the extracellular matrix and promote cancer cell invasion and metastasis, curcumin also demonstrates anti-metastatic qualities. Inflammation and the advancement of cancer are linked to the NF-κB signaling pathways, which are also suppressed by curcuminoids. Along with these processes, curcumin has demonstrated the ability to improve the effectiveness of traditional cancer treatments, including radiation and chemotherapy. It increases the sensitivity of cancer cells to various therapies, which enhances the therapeutic results. However, curcumin's low bioavailability limits its therapeutic use. Its anticancer potency may be increased, and this restriction may be overcome due to recent developments in drug delivery technologies, such as curcumin-loaded nanoparticles. Since they can target several different molecular pathways and improve the effectiveness of current treatments, curcuminoids are a promising family of chemicals for the prevention and treatment of cancer.
Italian Journal of Animal Science · مجلد 24 (1) · 1689-1707
This study is the first to explore the effects of dietary supplementation with chitosan nanoparticles (CHNPs) loaded with berberine (B) and curcumin (CR), either individually or in combination, within high-carbohydrate diets (HCD) on growth performance, health status, and immune-inflammatory gene expression in Nile tilapia. A total of 150 healthy Oreochromis niloticus fingerlings (8.21 ± 0.08 g) were randomly assigned to five groups: control (29% carbohydrate), HCD (42% carbohydrate), and three supplemented groups; B-CHNPs (100 mg berberine/kg HCD), CR-CHNPs (100 mg curcumin/kg HCD), and B-CR-CHNPs (100 mg berberine + curcumin (50:50)/kg HCD) for 100 days. The B-CR-CHNPs treatment significantly enhanced growth, feed utilisation, protein efficiency, digestive enzyme activities, blood protein levels, liver function, and lipid metabolism compared to the HCD group (p < 0.05). Dietary supplementation with Berberine and Curcumin effectively reversed the aberrant changes in liver tissues caused by HCD, restoring hepatic morphology to a state closely resembling normal conditions. Additionally, the dietary treatments significantly enhanced antioxidant status by reducing malonaldehyde levels and increasing total antioxidant capacity and superoxide dismutase activity. B-CR-CHNPs treatment effectively restored the suppressed expression of IgM and LZM genes in the liver of HCD-fed fish. In contrast, the elevated hepatic expression of pro-inflammatory genes TNF-α and IL-1β induced by the HCD was significantly reduced, with the greatest reduction observed in the B-CR-CHNPs group. Berberine and Curcumin showed strong binding to antioxidant, immune, and inflammatory targets. Supplementing Nile tilapia diets with 100 mg B-CR-CHNPs improved growth and mitigated HCD-induced liver damage by modulating metabolism, immunity, and redox balance.
BACKGROUND: Antimicrobial-resistant Helicobacter pylori (H. pylori) poses a significant public health concern, especially given the limited therapeutic options for azithromycin-resistant strains. Hence, there is a necessity for new studies to reconsider the use of azithromycin, which has diminished in effectiveness against numerous strains. Thus, we aimed to augment azithromycin's anti-Helicobacter properties by combining it with curcumin in different formulations, including curcumin in clove oil, curcumin nano-gold emulsion, and curcumin nanoemulsion. METHODS: The antimicrobial activities of the investigated compounds, both individually and in combination with other anti-Helicobacter drugs, were evaluated. Their antibiofilm and anti-virulence properties were assessed using both phenotypic and genotypic methods, alongside molecular docking studies. Our findings were further validated through mouse protection assays and histopathological analysis. RESULTS: We observed high anti-Helicobacter activities of curcumin, especially curcumin nanoemulsion. A synergistic effect was detected between curcumin nanoemulsion and azithromycin with fraction inhibitory concentration index (FICI) values <0.5. The curcumin nanoemulsion was the most active anti-biofilm and anti-virulence compound among the examined substances. The biofilm-correlated virulence genes (babA and hopQ) and ureA genes were downregulated (fold change <1) post-treatment with curcumin nanoemulsion. On the protein level, the anti-virulence activities of curcumin nanoemulsion were documented based on molecular docking studies. These findings aligned with histopathological scoring of challenge mice, affirming the superior efficacy of curcumin nanoemulsion/azithromycin combination. CONCLUSION: The anti-Helicobacter activities of all curcumin physical forms pose significant challenges due to their higher minimum inhibitory concentration (MIC) values exceeding the maximum permissible level. However, using curcumin nanoemulsion at sub-MIC levels could enhance the anti-Helicobacter activity of azithromycin and exhibit anti-virulence properties, thereby improving patient outcomes and addressing resistant pathogens. Therefore, more extensive studies are necessary to assess the safety of incorporating curcumin nanoemulsion into H. pylori treatment.
Cancer is the second leading cause of death in the world and one of the major public health problems. Curcumin has anticancer activity including inducing apoptosis and inhibiting proliferation and invasion of tumours by suppressing a variety of cellular signalling pathways. It also possesses anti-tumour activity on different human cancers such as breast cancer, lung cancer, head and neck squamous cell carcinoma, prostate cancer, and brain tumours. In vitro and in vivo trails, curcumin inhibits tumour development and metastasis by inhibiting many pathways that regulate signalling in malignant cells, including Ras, p53, extracellular signal-regulated kinases (ERK), Wnt-protein kinase B (Akt), MAPKs, and PI3K. Curcumin can also inhibit IKK, EGFR, -catenin, cyclin D1, tumour necrosis factor (TNF), and anti-apoptotic genes such as Bcl-X and Bcl-2 along with downregulating nuclear transcription factors like NF-κB, which reduces the formation of pro-inflammatory cytokines like chemokines, TNF-, Interleukins and IL-1, IL-2, IL-6, IL-8, IL-12.Abbreviations: AP-1, activated protein 1; Bax, BCL-2-associated X protein; Bcl-XL, B-cell leukaemia extralarge; Cdc, cell division cycle; COX, cyclooxygenase; CY, cytochrome; DPPC, dipalmitoylphosphatidylcholine; EGFR, epidermal growth factor receptor; eIF, eukaryotic initiation factors; FOX, Forkhead box; FPTase, farnesyl protein transferase; HIF, hypoxia-inducible factor; histone deacetylase inhibitors, HLJ, DnaJ-like heat shock protein; Hsp, heat shock proteins; IL, interleukin; miRNA, micro ribonucleic acid; MMC, mitomycin-C; mTOR, mammalian target of rapamycin; NF-κB, nuclear transcription factor-kappa–B; PG, prostaglandins; PKB, protein kinase B; Ras, reticular activating system; TargOncol, human small cell lung cancer cell lines; TGF, transforming growth factor; TNF, tumour necrosis factor; TP, thymidine phosphorylase; TPA3, 12-O-tetradecanoylphorbol-13-acetate; u-PA, urokinase-type plasminogen activator; VEGF, vascular endothelial growth factors; XIAP, Xlinked inhibitor of apoptosis
Malathion is one of the most used organophosphorus pesticides that is used for many reasons such as agriculture and industry. Human exposure to malathion may occur through various means, such as eating food that has been treated with it. Malathion not only increases oxidative stress but also decreases the antioxidant capacity. Curcumin is a powerful antioxidant with many pharmacological actions. Curcumin can act as a free radical scavenger and inhibit the activation and nuclear translocation of NF-κB. Curcumin could combat the lipid peroxidation and antioxidant depletion that trigger the apoptotic pathways. This study aims to examine the antioxidant, anti-inflammatory, and antiapoptotic effects of curcumin. Twenty-four Sprague Dawley rats were divided into four groups (six rats each): control, curcumin, malathion, and malathion + curcumin groups. At the assigned time, blood samples were used for the assessment of serum creatinine, and the kidneys were excised and washed; parts of them were used for the assessment of total oxidant status (TOS), oxidative stress index (OSI), the oxidative stress marker malondialdehyde (MDA), total antioxidant capacity (TAC), and glutathione (GSH) activity, other parts were fixed in formalin for further staining. Histopathological evaluation was performed for the fixed specimens after staining with H&E, sirus red, and the immunohistochemical staining for NF-κβ, TNF-α, Caspase-3, Nrf2, and HO-1. Curcumin significantly decreases the serum creatinine after malathion exposure and significantly restores the oxidant/antioxidant balance by increasing TAC and GSH and decreasing TOS, OSI, and MDA. Curcumin exerts its reno-protective effect and restores the histological architecture of the kidney by downregulating the immune expression of NF-κβ, TNF-α, and Caspase-3 and upregulating the expression of Nrf2 and HO-1. This study concluded that curcumin protects against nephrotoxicity caused by malathion by exerting its antioxidant, anti-inflammatory, and anti-apoptotic capabilities.
Kidney has a crucial role in immunity, so any toxicity occurs for the kidney will result in reduced immunity. The aim of this study is to improve the immune response of insufficient kidneys through immune-related genes. Diethyl Nitrosamine has been used to cause kidney damage in animal models, vitamin C and curcumin have been used to treat impaired kidney. Renal function (urea, uric acid and creatinine) and oxidative stress parameters (superoxide dismutase, malondialdehyde and glutathione peroxidase) will be evaluated in this research work. Molecular docking also will be performed to investigate the role of vitamin C and curcumin in targeting immune response proteins. Also, Complementary component 3, Lipocalin-2, Toll-like receptor 2,Toll-like receptor 4, Kidney injury molecule-1, Interleukin 6, Interleukin-10, Tumor necrosis factor and p38 mitogen-activated protein kinases will be investigated. The obtained results showed that vitamin C and curcumin have good effects in the treatment of impaired kidneys, this was also observed in renal function and oxidative stress parameters, expression levels of proteins and histopathological examinations.
Despite the fact that several analytical methodologies have been reported for the determination of curcumin (CCM) in a wide range of sample matrices, the greener liquid chromatographic approaches to determine CCM are scarce in the literature. Therefore, this research is designed to develop and validate a greener stability-indicating “high-performance liquid chromatography (HPLC)” methodology to determine CCM in an in-house developed nanoemulsion, Curcuma longa L. extract, and commercial tablets. CCM was measured on a Nucleodur (150 mm × 4.6 mm) RP C18 column with 5 µm-sized particles. Ethanol and ethyl acetate (83:17 v/v) made up the greener eluent system, which was pumped at a flow speed of 1.0 mL/min. At a wavelength of 425 nm, CCM was detected. The greener HPLC methodology was linear in the 1–100 µg/mL range, with a determination coefficient of 0.9983. The greener HPLC methodology for CCM estimation was also rapid (Rt = 3.57 min), accurate (%recoveries = 98.90–101.85), precise (%CV = 0.90–1.11), and sensitive (LOD = 0.39 µg/mL and LOQ = 1.17 µg/mL). The AGREE approach predicted the AGREE score of 0.81 for the established HPLC technique, indicating an outstanding greenness profile. The utility of the greener HPLC methodology was demonstrated by determining CCM in the in-house developed nanoemulsion, Curcuma longa extract, and commercial tablets. The % amount of CCM in the in-house developed nanoemulsion, Curcuma longa extract, and commercial tablets was found to be 101.24%, 81.15%, and 78.41%, respectively. The greener HPLC methodology was able to detect its degradation product under various stress conditions, suggesting its stability-indication characteristics. These results suggested that CCM in developed nanoemulsion, plant extract samples, and commercial tablets may be routinely determined using the greener HPLC methodology.
Indian Journal of Pharmaceutical Sciences · مجلد 85 (S2)
Curcumin has a powerful anti-inflammatory impact, despite its limited absorption when given orally. Earlier research has proved the efficacy of the curcumin extracts in the rat model and therefore the present study is an attempt to evaluate the effects of lyophilized curcumin extracts delivered through iontophoresis among patients suffering from rheumatoid arthritis. Lyophilized curcumin extracts having 29.79 % curcumin as its active ingredient was prepared using standardized method and it was applied to the inflamed hands of the rheumatoid arthritis patients, satisfying the inclusion criteria. Another group of patients were treated with oral curcumin. The prospective study was done among 20 patients at LifeLine Rehab Center who were diagnosed during January 2022 to August 2022. The experimental group use iontophoretically treated curcumin which showed significant improvement as compared to their matched controls. Iontophoretic application of lyophilized curcumin extracts has been found to provide a greater anti-arthritic impact due to improved curcumin penetration and bioavailability. Future studies can be conducted to examine the effects of different curcumin applications in arthritic conditions and examining their action pathways. english xxx, xxx videos hd videos, hindi xxx, xxx hindi video, indian sexy couple, sexy indian dancing girl nude
curcuminiontophoresisrheumatoid arthritistransdermal drug delivery
Quercetin is a phenolic flavonol compound with established antioxidant, anti-inflammatory, and immuno-stimulant properties. Recent studies demonstrate the potential of quercetin against COVID-19. This article highlighted the prophylactic/therapeutic potential of quercetin against COVID-19 in view of its clinical studies, inventions, and patents. The literature for the subject matter was collected utilizing different databases, including PubMed, Sci-Finder, Espacenet, Patentscope, and USPTO. Clinical studies expose the potential of quercetin monotherapy, and also its combination therapy with other compounds, including zinc, vitamin C, curcumin, vitamin D3, masitinib, hydroxychloroquine, azithromycin, and ivermectin. The patent literature also examines claims that quercetin containing nutraceuticals, pharmaceuticals, and dietary supplements, alone or in combination with other drugs/compounds, including favipiravir, remdesivir, molnupiravir, navitoclax, dasatinib, disulfiram, rucaparib, tamarixin, iota-carrageenan, and various herbal extracts (aloe, poria, rosemary, and sphagnum) has potential for use against COVID-19. The literature reveals that quercetin exhibits anti-COVID-19 activity because of its inhibitory effect on the expression of the human ACE2 receptors and the enzymes of SARS-CoV-2 (MPro, PLPro, and RdRp). The USFDA designated quercetin as a "Generally Recognized as Safe" substance for use in the food and beverage industries. It is also an inexpensive and readily available compound. These facts increase the possibility and foreseeability of making novel and economical drug combinations containing quercetin to prevent/treat COVID-19. Quercetin is an acidic compound and shows metabolic interaction with some antivirals, antibiotics, and anti-inflammatory agents. Therefore, the physicochemical and metabolic drug interactions between quercetin and the combined drugs/compounds must be better understood before developing new compositions.
In cancer management, drug resistance remains a challenge that reduces the effectiveness of chemotherapy. Several studies have shown that curcumin resensitizes cancer cells to chemotherapeutic drugs to overcome resistance. In the present study, we investigate the potential therapeutic role of curcumin in regulating the proliferation of drug-resistant cancers. Six drug-sensitive (MCF7, HCT116, and A549) and -resistant (MCF7/TH, HCT116R, and A549/ADR) cancer cell lines were treated with curcumin followed by an analysis of cytotoxicity, LDH enzyme, total reactive oxygen species, antioxidant enzymes (SOD and CAT), fibrosis markers (TGF-β1 protein, fibronectin, and hydroxyproline), and expression of cellular apoptotic markers (Bcl-2, Bax, Bax/Bcl-2 ratio, Annexin V, cytochrome c, and caspase-8). Additionally, the expression of cellular SIRT1 was estimated by ELISA and RT-PCR analysis. Curcumin treatment at doses of 2.7-54.3 µM significantly reduced the growth of sensitive and resistant cells as supported with decreased viability and increased cellular LDH enzyme of treated cells compared to controls non-treated cells. Curcumin also at doses of 2.7 and 54.3 µM regulated the fibrogenesis by reducing the expression of fibrotic markers in treated cells. Analysis of apoptotic markers indicated increased Bax, Bax, Bax/Bcl-2 ratio, Annexin V, caspase-8, and cytochrome c expression, while Bcl-2 expressions were significantly reduced. In curcumin-treated cells at 2.7 μM, non-significant change in ROS with significant increase in SOD and CAT activity was observed, whereas an increase in ROS with a reduction in respective antioxidant enzymes were seen at higher concentrations along with significant upregulation of SIRT1. In conclusion, the present study shows that curcumin induces anticancer activity against resistant cancer cell lines in a concentration- and time-dependent manner. The protective activities of curcumin against the growth of cancer cells are mediated by modulating oxidative stress, regulating fibrosis, SIRT1 activation, and inducing cellular apoptosis. Therefore, curcumin could be tested as an auxiliary therapeutic agent to improve the prognosis in patients with resistant cancers.